Advances in novel parentral drug delivery systems

Main Article Content

Rakesh Patel
Kaushal P Patel


The parenteral administration route is the most effective and common form of delivery for active drug substances with poor bioavailability and the drugs with a narrow therapeutic index. Drug delivery technology that can reduce the total
number of injection throughout the drug therapy period will be truly advantageous not only in terms of compliance, but also to improve the quality of the therapy. Such reduction in frequency of drug dosing is achieved by the use of specific formulation technologies that guarantee the release of the active drug substance in a slow and predictable manner. The development of new injectable drug delivery system has received considerable attention over the past few years. A number of technological advances have been made in the area of parenteral drug delivery leading to the development of sophisticated systems that allow drug targeting and the sustained or controlled release of parenteral medicines.


Download data is not yet available.

Article Details

How to Cite
Patel, R., & Patel, K. P. (2014). Advances in novel parentral drug delivery systems. Asian Journal of Pharmaceutics (AJP), 4(3).


Kapoor S. An overview on advanced parenteral drug delivery system

in clinical disease management. Pharmainfo Net. 2007.

Panayiotis PC, Mahesh VC, Robert S. Advances in lipid nanodispersions

for parenteral drug delivery and targetting. Science 2008;60:757-67.

Collins GL, Feichtinger N, Wärnheim T. Are lipid emulsions the drug

delivery solution?. Mod Drug Discov 2000;3:44-8.

Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral

drug delivery. Adv Drug Deliv Rev 2004;56:1257-72.

Attama AA, Reichl S. Diclofenac sodium delivery to the eye: in vitro

evaluation of novel solid lipid nanoparticle formulation using human

cornea construct. Int J Pharm 2008;355:307-13.

Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. Solid lipid

nanoparticles for pulmonary delivery of insulin. Int J Pharm


Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of

actives. Eur J Pharm Biopharm 2008;71:161-72.

Wong HL. Solid lipid nanoparticles for antitumor drug delivery. In:

Amiji M, editor. Nanotechnology for Cancer Therapy. USA: CRC Press;

p. 714-76.

Shenoy VS, Vijay IK, Murthy RSR. Tumour targeting: biological factors

and formulation advances in injectable lipid nanoparticles. J Pharm

Pharmacol 2005;57:411-22.

Zhang X, Miao J, Yuan H. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 2008;361:239-44.

Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM. Effect of cationic

lipid and matrix lipid composition on solid lipid nanoparticle-mediated

gene transfer. Eur J Pharm Biopharm 2004;57:55-162.

Lu W, He LC, Wang CH, Li YH, Zhang SQ. The Use of Solid Lipid

Nanoparticles to Target a Lipophilic Molecule to the Liver after

Intravenous Administration to Mice. Int J Biological Macromol


Müller RH, Keck CM. Drug delivery to the brain-realization by novel

drug carriers. J Nanosci Nanotechnol 2004;4:471-83.

Panyam J, Chavanpatil M. Lipid-derived nanoparticles for brain-targeted

drug delivery. PCT 2008:WO2008024753.

Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935-40.

Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid

nanoparticles in brain targeting, J Control Release 2008;127:97-109.

Zhang W, Liu J, Li S, Chen M, Liu H. Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: influence of Poloxamer 188 coating on phagocytic uptake. J Microencapsul 2008;25:203-9.

Liu W, He Z, Liang J. Preparation and characterization of novel

fluorescent nanocomposite particles: CdSe/ZnS core-shell quantum dots

loaded solid lipid nanoparticles. J Biomed Mater Res. 2008;84:1018-25.

Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and

polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev


Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid

nanoparticles as passive targeting therapeutic agents for rheumatoid

arthritis. Int J Pharm 2008;352:273-9.

Zhang W, Liu J, Li S, Chen M, Liu H. Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: influence of Poloxamer 188 coating on phagocytic uptake. J Microencapsul 2008;25:203-09.

Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR,

et al. Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion

of human neutrophils to endothelial cells. Br J Pharmacol 2006;148:


Weyhers H, Ehlers S, Hahn H, Souto EB, Müller RH. Solid lipid

nanoparticles (SLN) – effects of lipid composition on in vitro

degradation and in vivo toxicity. Pharmazie 2006;61:539-44.

Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming

parenteral drug delivery systems: an overview. Eur J Pharm Biopharm


Moreau M, Abdellaoui KS, Schneider, Boisramc B, Gurny R. Controlled

delivery of metoclopramide using an injectable semi-solid poly(ortho

ester) for veterinary application. Int J Pharm 2002;248:31-7.

Dunn R. The Atrigel Drug Delivery System. In: Drugs and the

Pharmaceutical Sciences. New York, MA: Dekker Series; 2003. p. 647-55.

Gentner G. Biodegradable block copolymers for delivery of proteins

and water-insoluble drugs. J Control Release 2001;72:203-15.

Murdan S. Organogels in drug delivery. Expert Opin Drug Deliv


Chow HF, Zhang J, Lo CM. Improving the gelation properties of

,5-diaminobenzoate-based organogelators in aromatic solvents with

additional aromatic-containing pendants. Tetrahedron 2007;63:363-73.

Anda V, Leroux JC. Organogels and their use in drug delivery — A

review. J Contro Release 2007;125:179-92.

Rossi J. Principles in the development of intravenous lipid emulsions.

In: Wasan K. editor. Role of Lipid Excipients in Modifying Oral and

Parenteral Drug Delivery. Hoboken, New Jersey: Wiley-Interscience;

p. 88-123.

Torchilin VP. Lipid-based parenteral drug delivery systems: biological

implications. In: Wasan K, editor. Role of Lipid Excipients in Modifying

Oral and Parenteral Drug Delivery. Hoboken, New Jersey: Wiley-

Interscience; 2007. p. 48-87.

Tadros T, Izquierdo P, Esquena J, Solans C. Formation and stability of

nanoemulsions. Adv. Colloid Interface Sci 2004;109:303-18.

Rabinow BE. Nanosuspensions in drug delivery. Nature Rev 2004;3:


Sarker DK. Engineering of nanoemulsions for drug delivery. Cur Drug

Deliv 2005;2:297-310.

Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, Ali J, Baboota S, Ahuja A,

et al. Formulation development and optimization using nanoemulsion

technique: a technical note. AAPS Pharm Sci Tech 2007;8:28.

Rons R, Carrera I, Caelles J, Rouch J, Panizza P. Formation and properties of miniemulsions formed by microemulsions dilution. Adv Colloid

Interface Sci 2003;106:129-43.

Rabinow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, et al.

Itraconazole IV nanosuspension enhances efficacy through altered

pharmacokinetics in the rat. Int J Pharm 2007;339:251-60.

Moschwitzer J, Muller RH. New method for the effective production of

ultrafine drug nanocrystals. J Nanosci Nanotechnol 2006;6:3145-53.

Mouton JW, Van PA, Beule K, Van VA, Donnelly JP, Soons PA.

Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy

subjects after single and multiple doses of a novel formulation.

Antimicrob. Agents Chemother 2006;50:4096-102.

Patel RP. Niosomes: An Unique Drug Delivery System.

Shahiwala A, Misra AN. Studies in topical application of niosomally

entrapped nimesulide. J Pharm Pharmaceu Sci 2002;5:220-5.

Tamizharasi S, Dubey A, Rathi V, Rathi JS. Development and

characterization of niosomal drug delivery of Gliclazide. J Young Pharm


Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems

for cancer targeted drug delivery. Pharm. Res 2007;24:1029-46.

Doijad RC, Manvi FV, Swati S, Rony MS. Niosomal drug delivery

of Cisplatin: Development and characterization. Indian Drugs


Ismail AA, Sanaa A, Gizawy E, Fouda MA, Donia AM. Influence of a

niosomal formulation on the oral bioavailability of acyclovir in rabbits.

AAPS PharmSci Tech 2007;8:1-7.

Roopa K, Mamatha GC, Subramanya G, Udupa N. Preparation,

characterization and tissue disposition of niosomes containing

Isoniazid. Rasayan J Chem 2008;1:224-7.

Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm

Res 2007;24:1-16.

Zamboni WC. Liposomal, nanoparticle and conjugated formulation of

anticancer agents. Clin Cancer Res 2005;11:8230-34.

Mamot C, Drummond DC, Hong K, Kirlotin DB, Park JW. Liposome

based approaches to overcome anticancer drug resistance. Drug Resist

Update 2003;6:271-9.

Pastorino F, Brignole C, Marimpietri D. Doxorubicin-loaded Fab’

fragments of anti-disialoganglioside immunoliposomes selectively

inhibit the growth and dissemination of human neuroblastoma in nude

mice. Cancer Res 2003;63:86-92.

Brouckaert P, Takahashi N, Van Tiel ST. Tumor necrosis factor-a

augmented tumor response in B16BL6 melanoma-bearing mice treated

with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil

pharmacokinetics. Int J Cancer 2004;109:442–8.

Straubinger RM, Arnold RD, Zhou R. Antivascular and antitumor activities

of liposome-associated drugs. Anticancer Res 2004;24:397-404.

Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh

B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate

for the targeted delivery of rivastigmine in to the brain to treat

Alzheimer’s disease. Brain Res 2008;1200:159-68.

Rathod S, Deshpanden SG. Design and evaluation of liposomal

formulation of pilocarpine nitrate. In J Pharm Sci 2010;72:155-60.

Samad A, Sultana Y, Aqil M. Liposomal Drug Delivery Systems: An update

review. Curr Drug Deliv 2007;4:297-305. (Parenteral Drug Delivery III: Novel Parenteral

Products, Devices, and Insulin).